The Liquid Biopsy: The Promise and Challenge behind CTCs and cfDNA

Kalorama Information offers comprehensive analysis of the cancer diagnostics market, including cancer testing services, with The World Market for Cancer Diagnostics, 6th Edition. Liquid biopsy technology is also reviewed in The World Market for Molecular Diagnostics, 6th Edition. A free Kalorama Information white paper regarding the market for laboratory-developed oncology tests is available here.

While previous non-invasive sampling technologies represented IVD market boons, liquid biopsies for cancer testing may prove to be the grail of the clinical diagnostics market. Liquid biopsy is an alternative to traditional biopsies or invasively collected tissue samples, instead a venous blood draw is used. The diagnosis of cancer in asymptomatic patients is a proposed role for liquid biopsies and a new frontier for IVD, but does not encompass the potentially greater value of the technology in driving the next stage of personalized medicine.

POC Juggernaut Forged with Alere Purchase

Abbott is marking out point-of-care as an area that it can compete and win in with its purchase of Waltham, MA-based Alere, Inc.  This should not be surprising as POC in some areas, such as infectious disease, is growing revenue at one and one-half times the global IVD market.

India and China IVD Markets Defy Economic Headlines

While in vitro diagnostic testing is not immune to general economic conditions, it is somewhat shielded by its own set of market dynamics not always attached to stock prices and quarterly results.  Healthcare spending and hospital construction, underserved populations and increasing urban migration drive tests.   Kalorama has just released IVD in India:  http://www.kaloramainformation.com/IVD-India-9596771/   Our current study of Indian IVD markets finds growth despite recent concerns about Asian markets broadly.

Take Stock of the LDT Market Landscape with the New Kalorama Information White Paper

Kalorama Information offers comprehensive analysis of the cancer diagnostics market, including cancer testing services, with The World Market for Cancer Diagnostics, 6th Edition. The free white paper regarding laboratory-developed oncology tests is available here.

The test service model has become a leading strategy for laboratories and even some IVD companies looking to expand their footprint in the cancer diagnostics market. In the leading U.S. market, company-owned test services have long served as a vehicle for the commercialization of advanced and highly complex assays. Reference labs in the United States were the first to launch many groundbreaking tests in the areas of viral load testing, anatomical pathology specialty analyses, and molecular diagnostics. First-generation tests target relatively small target markets where the financial investment for FDA market clearance of a commercial test kit or diagnostic device could far outstrip revenue. Consequently, labs and IVD companies have instead opted to first offer the test as a service from a CLIA-certified facility.

No Concern for Device Industry Seen in J&J Restructuring

The recent medical device-related layoffs at Johnson & Johnson is an impactful decision for the company and on its employees.  But it does not signal any downturn in the medical device market, as the New Brunswick, N.J. - based device giant has been selling off parts of its devices business in recent years, and J&J's declines should reflect increases in other companies.

Pages

Subscribe to Kalorama Information Home RSS